May 31, 2023
Walvax publishes data on safety, immunogenicity and immune persistence from the Phase 2 trial of its bivalent HPV vaccine Walrinvax™ in Human Vaccines & Immunotherapeutics
Learn More
May 19, 2023
Walvax’s PCV13-TT Receives Endorsement from the Pediatric Infectious Disease Society of Thailand
Learn More
Apr 14, 2023
Walvax publishes safety and preliminary immunogenicity results from the Phase 1 trial of its bivalent HPV vaccine Walrinvax™ in journal Vaccine
Learn More
Media Contact
Media Team
media@walvax.com
